Adaptive Phage Therapeutics
Mike Sowers is an experienced professional in the field of Quality Assurance and Quality Operations, currently serving as the Director of Quality at Adaptive Phage Therapeutics since June 2021. Prior to this role, Mike held several senior positions, including Sr. Director of Quality Services at NOVAVAX INC and Director of Quality Assurance at Sanaria Inc. Additionally, Mike has extensive experience at Lonza as Sr. QA Manager for Bioscience R&D and at Novavax as Sr. Director of Quality Operations. Earlier career roles included Sr. Director of Quality Assurance at GenVec and Production Manager at Dexall Biomedical, along with a start as a Lab Technician at Cambridge Biotech. Mike Sowers earned a degree from West Virginia Wesleyan College between 1986 and 1990.
This person is not in any teams
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.